Endorsed by the American College of Medical Genetics and Genomics (ACMG) in 2016, Non-Invasive Prenatal Testing (NIPT) offers a safe screening for trisomies 13, 18, and 21 from week 10 of pregnancy, without risking the child's health. ACMG highlights NIPT's superior sensitivity and recommends its availability and related counseling to all pregnant patients. This approach minimizes unnecessary amniocentesis, providing early, accurate insights with ease.